Literature DB >> 15383746

Depressive symptoms increase the likelihood of cognitive impairment in elderly people with subclinical Alzheimer pathology.

Elizabeth J Milwain1, Zsuzsanna Nagy.   

Abstract

The objective of this study was to investigate whether the presence of depressive symptoms influences the clinical expression of Alzheimer's pathology. We have analysed the relationships between the severity of Alzheimer's pathology and cognitive decline in two patient groups defined by the presence or absence of depressive symptoms. The study included 89 subjects who participated in a longitudinal research programme prior to death, underwent post-mortem examination and were found to have only Alzheimer-type pathology in their brains, ranging in severity from the entorhinal to neocortical stages. Our results indicate that depressive symptoms did not influence cognition in the early (entorhinal) stages of Alzheimer's disease (AD; where cognition was good regardless of whether or not there was evidence for depressive symptoms) or in the late (neocortical) stages (where cognition was poor regardless of whether or not there was evidence for depression). However, in the intermediate (limbic) stages, patients with depressive symptoms had significantly worse cognitive performance (mean CAMCOG of 32) than those who did not (mean CAMCOG of 73). We conclude that depressive symptoms may contribute to the cognitive decline of AD patients in that pathology, that would be otherwise silent, becomes clinically apparent. Therefore, a multiple diagnosis of early AD and depression should be more widely considered in elderly persons presenting with mild cognitive decline and depression. Treating the depressive symptoms would benefit the patient, but the cognitive improvement may not indicate that AD is absent. Copyright 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2004        PMID: 15383746     DOI: 10.1159/000080971

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  7 in total

Review 1.  Telomere shortening and Alzheimer's disease.

Authors:  Zhiyou Cai; Liang-Jun Yan; Anna Ratka
Journal:  Neuromolecular Med       Date:  2012-11-16       Impact factor: 3.843

2.  Cognitive decline in patients with dementia as a function of depression.

Authors:  Michael A Rapp; Michal Schnaider-Beeri; Michael Wysocki; Elizabeth Guerrero-Berroa; Hillel T Grossman; Andreas Heinz; Vahram Haroutunian
Journal:  Am J Geriatr Psychiatry       Date:  2011-04       Impact factor: 4.105

Review 3.  Anxiety and depression in Alzheimer's disease: a systematic review of pathogenetic mechanisms and relation to cognitive decline.

Authors:  Rossana Botto; Nicoletta Callai; Aurora Cermelli; Lorenzo Causarano; Innocenzo Rainero
Journal:  Neurol Sci       Date:  2022-04-23       Impact factor: 3.830

Review 4.  Pharmacological Treatment of Depression in Alzheimer's Disease: A Challenging Task.

Authors:  Tommaso Cassano; Silvio Calcagnini; Antonio Carbone; Vidyasagar Naik Bukke; Stanislaw Orkisz; Rosanna Villani; Adele Romano; Carlo Avolio; Silvana Gaetani
Journal:  Front Pharmacol       Date:  2019-09-27       Impact factor: 5.810

5.  Plasma biomarkers of depressive symptoms in older adults.

Authors:  S E Arnold; S X Xie; Y-Y Leung; L-S Wang; M A Kling; X Han; E J Kim; D A Wolk; D A Bennett; A Chen-Plotkin; M Grossman; W Hu; V M-Y Lee; R Scott Mackin; J Q Trojanowski; R S Wilson; L M Shaw
Journal:  Transl Psychiatry       Date:  2012-01-03       Impact factor: 6.222

6.  Differences in prefrontal, limbic, and white matter lesion volumes according to cognitive status in elderly patients with first-onset subsyndromal depression.

Authors:  Jun-Young Lee; Soowon Park; Scott Mackin; Michael Ewers; Helena Chui; William Jagust; Philip S Insel; Michael W Weiner
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

7.  Mid to late-life scores of depression in the cognitively healthy are associated with cognitive status and Alzheimer's disease pathology at death.

Authors:  Andrew C Robinson; Federico Roncaroli; Yvonne S Davidson; James Minshull; Calvin Heal; Daniela Montaldi; Antony Payton; Michael A Horan; Neil Pendleton; David M A Mann
Journal:  Int J Geriatr Psychiatry       Date:  2020-11-20       Impact factor: 3.485

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.